DESLEY BLANCH : When would you be doing Phase 2 and 3 trials?
DR ESRA OGRU : Phase 2 is actually scheduled for later this year and Phase 3 will continue on from the end of this year and all of next year and onwards.
The beauty with working with transtermal systems is the regulatory hurdles are much less complex than developing a novel product and since Oxycodone has been around for a very, very long time, we do have that advantage of knowing what to expect. So we've got a path forward mapped out for the next three to four years and we hope to have it registered by then.
http://www.radioaustralia.net.au/innovations/stories/s2920385.htm
Add to My Watchlist
What is My Watchlist?
